|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
norepinephrine reuptake inhibitor
|
|
gptkbp:approvalYear
|
1985
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06AX12
|
|
gptkbp:availableOn
|
extended-release tablet
immediate-release tablet
sustained-release tablet
|
|
gptkbp:brand
|
gptkb:Wellbutrin
gptkb:Zyban
|
|
gptkbp:CASNumber
|
34841-39-9
|
|
gptkbp:chemicalFormula
|
C13H18ClNO
|
|
gptkbp:compatibleWith
|
antidepressant
selective serotonin reuptake inhibitor
|
|
gptkbp:contraindication
|
eating disorders
seizure disorder
|
|
gptkbp:developedBy
|
gptkb:United_States
|
|
gptkbp:discoveredBy
|
gptkb:Burroughs_Wellcome
|
|
gptkbp:discoveredIn
|
1969
|
|
gptkbp:drugClass
|
aminoketone
|
|
gptkbp:eliminationHalfLife
|
21 hours
|
|
gptkbp:firstSynthesized
|
gptkb:Nariman_Mehta
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
bupropion
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:monoamine_oxidase_inhibitors
other drugs that lower seizure threshold
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
1985
GlaxoSmithKline
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of norepinephrine and dopamine
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
children under 18
|
|
gptkbp:patentExpired
|
2006
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
anxiety
hypertension
tremor
weight loss
sweating
rash
agitation
allergic reactions
increased risk of seizures at high doses
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
headache
seizures
insomnia
dry mouth
|
|
gptkbp:usedFor
|
gptkb:depression
gptkb:major_depressive_disorder
smoking cessation
|
|
gptkbp:bfsParent
|
gptkb:CYP2D6
|
|
gptkbp:bfsLayer
|
5
|